BACKGROUND The mammalian target of rapamycin (mTOR) pathway is up‐regulated in
castration‐resistant prostate cancer (CRPC). Nevertheless, inhibition of mTOR is ineffective …

Treatment of metastatic castrate resistant prostate cancer (mCRPC) after progression on
docetaxel chemotherapy is a challenging clinical scenario with limited availability of …

Objectives To retrospectively review the oncologic outcomes of docetaxel-based
chemotherapy in Japanese men with metastatic castration-resistant prostate cancer …

Background Docetaxel-based chemotherapy remains the standard of care for metastatic
castration-resistant prostate cancer (mCRPC) and it is the only globally approved first-line …

Background Pre-clinical data suggest that docetaxel and enzalutamide interfere with
androgen receptor translocation and signalling. The aim of this study is to assess the …

Purpose A randomized, placebo-controlled study based on preclinical and clinical data that
supports the potential role of vascular endothelial growth factor in prostate cancer was …

Docetaxel-based chemotherapy has been the standard of care for metastatic castration-
resistant prostate cancer (mCRPC) since 2004. Over the past few years, there has been a …

4525^ Background: Docetaxel is standard first-line chemotherapy for mCRPC. The Phase III
TROPIC trial showed that, for patients who progressed during or after docetaxel-based …

Study Type–Therapy (case series) Level of Evidence 4 What's known on the subject? and
What does the study add? Docetaxel rechallenge has shown preserved anti‐tumour activity …

Despite the proven success of hormonal therapy for prostate cancer using chemical or
surgical castration, most patients eventually will progress to a phase of the disease that is …